Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.

Autor:	Shoji R; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan yebyayayeby@gmail.com., Tsuchie H; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Nagasawa H; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Hongo M; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Kasukawa Y; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Nozaka K; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Kudo D; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Saito H; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Abe K; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Igarashi S; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Harata S; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Kasama F; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan., Miyakoshi N; Department of Orthopaedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2022 Nov; Vol. 42 (11), pp. 5357-5363.
DOI:	10.21873/anticanres.16041
Abstrakt:	Background/aim: This study evaluated the effect of haematogenous administration of acridine orange (AO) alone and in combination with zoledronate (ZOL) on bone metastases. Materials and Methods: E0771 cells (1.0×10 5 cells/10 μl) were injected directly into the right femur of female mice. The mice were divided into five groups according to treatment (drugs and irradiation) and were reared and sacrificed after 6 weeks. Micro-computed tomography (μCT) was performed to calculate the destruction rate of the femur bone. We measured tumour weight and volume at sacrifice and performed terminal deoxynucleotidyl transferase dUTP Nick-End Labelling staining of tumours. Results: At 4 weeks, the bone destruction rate was lower in the AO+ZOL group than in the radiation group. At 6 weeks, the AO+ZOL group had a lower bone destruction rate than the control and radiation groups; the ZOL group had a lower rate than the radiation group. The AO and AO+ZOL groups had suppressed tumour weight and volume compared to the control and radiation groups. The number of extraosseous apoptotic cells was higher in the AO+ZOL group than in all other groups except the AO group. Conclusion: In a model of local bone metastasis of breast cancer, haematogenous administration of AO reduced tumour size and more so when combined with ZOL. (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu